Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis

By Wu Kai-Da   Zhou Li   Burtrum Douglas   Ludwig Dale   Moore Malcolm  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 3, 2007-03 ,pp. : 343-357

Springer Publishing Company

Access to resources Recommend Favorite

Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

By                    

Oncology Letters, Vol. 3, Iss. 3, 2012-01 ,pp. : 713-717

Spandidos Publications

Access to resources Recommend Favorite

Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report

By            

Oncology Letters, Vol. 9, Iss. 5, 2015-01 ,pp. : 2239-2243

Spandidos Publications

Access to resources Recommend Favorite

Pancreatic Cancer Epidermal Growth Factor Receptor ( EGFR ) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response

By Tzeng Ching-Wei   Frolov Andrey   Frolova Natalya   Jhala Nirag   Howard J.   Vickers Selwyn   Buchsbaum Donald   Heslin Martin   Arnoletti J.  

Annals of Surgical Oncology, Vol. 14, Iss. 7, 2007-07 ,pp. : 2150-2158

Springer Publishing Company

Access to resources Recommend Favorite

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

By Clarke Jennifer   Pao William   Wu Nian   Miller Vincent   Lassman Andrew  

Journal of Neuro-Oncology, Vol. 99, Iss. 2, 2010-09 ,pp. : 283-286

Springer Publishing Company

Access to resources Recommend Favorite